122 results about "RNA virus" patented technology

The invention discloses application of a small molecule compound in prevention and treatment of plant RNA virus infection, and belongs to the technical field of biology. According to the invention, 2 '-amino-2'-deoxyguanosine (ADG) is used as a unique antiviral active component to be applied to prevention and treatment of plant RNA viruses for the first time, and broad-spectrum inhibition of various plant RNA viruses such as turnip mosaic virus (TuMV), tomato mosaic virus (ToMV) and tobacco mosaic virus (TMV) can be realized only by a low concentration of 250 [mu] M and a simple exogenous spraying mode; and after spraying, the normal growth of plants is not influenced, the risk of phytotoxicity is thoroughly avoided, the safety, high efficiency and broad spectrum of plant RNA virus prevention and control are remarkably improved, and important practical application significance is achieved for guaranteeing the yield and quality of crops in agricultural production and promoting agricultural green transformation.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

Synthetic Southern Phaseoloviridae satellite RNA molecules and satellite particles containing the same are disclosed. Synthetic Southern Phaseoloviridae satellite RNA molecules containing an internal heterologous RNA virus (HRV) amplicon are also disclosed. Also disclosed are methods of using Southern Phaseoloviridae satellite RNA molecules and satellite particles containing the same to alter plant phenotypes, improve stress resistance in plants, and improve pest and pathogen resistance in plants.

The application discloses a method for producing pectin oligosaccharides by microbial degradation of pomace and application thereof. The method comprises the following steps: adding microbacterium A5 to a culture medium containing pomace to perform fermentation to obtain a fermentation liquor, performing fractional pressing filtration and filter sterilization on the fermentation liquor, performing ethanol precipitation to extract a pectin crude product, removing protein, performing ion exchange chromatography, dialysis desalting, freeze drying and the like to purify two pectin oligosaccharides POS-1 and POS-2 with a purity greater than 95%; the pectin oligosaccharides POS-1 and POS-2 have strong scavenging capacity on hydroxyl radicals and DPPH free radicals and the capacity of inhibiting the activity of respiratory RNA viruses such as influenza virus H1N1 and respiratory syncytial virus RSV, and can be applied to medicines or health foods.

The invention discloses a plant endogenous small molecule polypeptide and application thereof in inhibiting RNA virus infected plants, the sequence of the small molecule polypeptide is Pep1-3: IIGVSNFDPVKRS, and the small molecule polypeptide is derived from nicotiana benthamiana; the invention relates to application of plant endogenous small molecule polypeptide in inhibiting RNA virus infection of plants. The plant is tobacco; the RNA viruses comprise tobacco mosaic viruses, tomato mosaic viruses and turnip mosaic viruses, and the small peptide Pep1-3 serves as a novel plant immunity inducer and shows the potential of the small peptide Pep1-3 in the aspect of preventing and controlling the RNA viruses. In agricultural production, prevention and treatment of virus diseases by adopting oligopeptide substances are a green and sustainable direction, and compared with traditional pesticides and plant immunity inducers, the composition has the advantages of broad spectrum, small toxicity, no drug resistance risk and long lasting period, and can generate a synergistic or synergistic effect when being mixed with other medicaments.

Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering Rigosertib or a composition thereof to a subject (e.g., a human subject).

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

The application discloses application of a fungal virus in prevention and treatment of pear tree and apple tree Valsa diseases. The fungal virus is a positive single-stranded RNA virus, and a cDNA nucleotide sequence of the fungal virus is shown as SEQ ID No. 1. A fungus containing the virus is Valsa pyri HJL1-22 (gamma), the fungus is infected by the fungal virus of claim 1, the fungus is named as HJL1-22 (gamma), is classified and named as Valsa pyri, and has a preservation number of CGMCC No. 41449 in China General Microbiological Culture Collection Center. The virus Vphv1-gamma can be secreted to outside of cells, therefore, culture liquid filtered off mycelium can be used as a biocontrol agent for prevention and treatment of pear tree and apple tree Valsa diseases, and can effectively weaken or inhibit pathogenicity and diffusion of Valsa pyri and Valsa mali, and has a prospect for being used for producing and practicing biological prevention and treatment of pear tree and apple tree Valsa diseases.

Disclosed are synthetic Marivirus eye satellite RNA molecules and satellite particles containing the same. Also disclosed are synthetic mateur virus satellite RNA molecules containing an internal heterologous RNA virus (HRV) amplicon. Also disclosed are methods of altering plant phenotypes, improving stress resistance in plants, and improving pest and pathogen resistance in plants using the Marivirus eye satellite RNA molecules and satellite particles containing the same.

The invention provides an application of trichostatin A in promotion of RNA virus proliferation, and belongs to the field of chemical medicines. The invention discloses a novel application of trichostatin A. The trichostatin A can effectively promote the-1 Ribosomal Frameshift process of RNA viruses, can effectively promote replication and proliferation of the RNA viruses, can be used for preparing products for promoting proliferation of the RNA viruses and can be used for producing and preparing RNA virus inactivated vaccines or attenuated vaccines, and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses. And the production cost can be effectively reduced, the production period is shortened, and wide application prospects and economic values are achieved.

The invention discloses a detection reagent, a kit and a detection method for pathogens of micropterus salmoides. The micropterus salmoides pathogen detection reagent comprises primers and probes for specifically amplifying an infectious spleen and kidney necrosis virus, a viral nervous necrosis virus, flavobacterium columnar, a perch rhabdovirus, a micropterus salmoides double-RNA virus, edwardsiella tarda, nocardia and a micropterus salmoides iridovirus; specific upstream and downstream primers and probes of the eight pathogens are sequences as shown in SEQ ID NO.1 to SEQ ID NO.24 in sequence. The micropterus salmoides pathogen detection reagent and method can detect eight pathogens at the same time, have the advantages of high sensitivity, high specificity, good repeatability and the like, provide reliable basis for prevention and control of the pathogens, also improve the prevention and control work efficiency, and have good application prospects. The kit is especially suitable for large-scale rapid screening and mixed infection diagnosis of aquaculture pathogens, and has important value and significance for prevention and treatment of micropterus salmoides pathogens.

The application discloses an antiviral polypeptide targeting virus-host interaction and application, the polypeptide is composed of 1-17 amino acids of ARF1, a transmembrane peptide TAT and an intermediate connecting peptide, and the amino acid sequence is shown as SEQ ID NO:1; the polypeptide provides a new strategy for the prevention and control of RNA viruses, and also provides a new theoretical basis for accelerating the research and development of broad-spectrum antiviral polypeptide small molecule drugs.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

Synthetic Tombusviridae satellite RNA molecules and satellite particles containing the same are disclosed. Also disclosed are synthetic Tombusviridae satellite RNA molecules containing internal heterologous RNA virus (HRV) amplicons. Methods of using the Tombusviridae satellite RNA molecules and satellite particles containing the same to alter plant phenotype, improve stress resistance of plants, and improve pest and pathogen resistance of plants are also disclosed.

The invention discloses a nucleoside antiviral NHC diester prodrug as shown in a formula I and pharmaceutically acceptable salts thereof, and a preparation method and medical application of the nucleoside antiviral NHC diester prodrug. Pharmacological experiments prove that the compound disclosed by the invention has relatively strong inhibitory activity on replication of multiple RNA viruses. Particularly, the compound has good lung microsome release efficiency, the species difference of the lung release efficiency is small, the consistency of the in-vivo drug effect of the antiviral drug and the in-vivo drug effect of the antiviral drug can be improved, and the risk of species difference of prodrug release antiviral active ingredients is avoided. Therefore, the compound provided by the invention has good broad-spectrum antiviral activity, and can be used as a broad-spectrum antiviral drug for treating various respiratory virus infections.

This invention relates to the field of biotechnology, and more particularly to a mutant of the Rift Valley fever virus L protein and its applications. The amino acid sequence of the mutant is based on the amino acid sequence shown in SEQ ID NO:1, with mutations made at position 1189 (aspartic acid) and / or position 1205 (tryptophan). Through cryo-electron microscopy structural analysis and in vitro mismatch experiments, this invention has confirmed that both identified key amino acid sites are involved in regulating the synthetic fidelity of viral polymerase: mutation at N1189 decreases the synthetic fidelity of the polymerase, while mutation at W1205 increases it. This invention not only provides a new target for the development of attenuated vaccines but also provides crucial evidence for elucidating the molecular regulatory mechanisms of RNA virus fidelity.

The invention provides a multiplex RPA (recombinase polymerase amplification) detection primer probe group, a test strip, a kit and a detection method for three prawn RNA (ribonucleic acid) viruses, and belongs to the technical field of biological detection. The invention provides a multiple RPA (recombinase polymerase amplification) detection primer probe group for three prawn RNA (ribonucleic acid) viruses. The multiple RPA detection primer probe group is designed by taking an IMNV MCP gene, a CMNV RdRp gene and a PvPV RdRp gene as target genes. The primer probe set designed by the invention meets the requirements of multiple RPA detection, and can specifically amplify corresponding viral nucleic acid. The invention also provides multiple RPA (recombinase polymerase amplification) detection capable of completing the three RNA viruses of prawns. When the triple RPA detection method constructed by the invention is used for detecting IMNV and CMNV in a sample, the result is completely consistent with the result of an RT-qPCR detection method. The triple RPA detection method established by the invention can be used for simultaneously detecting three viruses in a shorter time, and has a remarkable on-site detection advantage.

Synthetic turnip yellow mosaic virus satellite RNA molecules and satellite particles containing the same are disclosed. Synthetic turnip yellow mosaic virus satellite RNA molecules containing an internal heterologous RNA virus (HRV) amplicon are also disclosed. Also disclosed are methods of altering plant phenotypes, improving stress resistance in plants, and improving pest and pathogen resistance in plants using turnip yellow mosaic virus satellite RNA molecules and satellite particles containing the same.

The application discloses a kind of RNA virus nucleic acid preservative in fecal sample, including denaturant, chelating agent, pH buffering agent, osmotic pressure regulator and reducing agent;The denaturant includes guanidine salt and surfactant;The application further additionally provides a kind of RNA virus nucleic acid preservative in fecal sample preparation method, preparation above-mentioned one kind of RNA virus nucleic acid preservative in fecal sample, including the following steps: each component is mixed with ratio, pH is adjusted with pH buffering agent, with deionized water constant volume;Filter, obtain the preservative solution described in this application.The preservative solution of the application can stably store human cell DNA and viral RNA in fecal sample at room temperature for at least 7 days, which is beneficial for long-distance transportation at room temperature;Meanwhile, the preservative solution of the application also releases nucleic acid, inactivates virus, so as to prevent biological leakage and infection phenomenon;The de-inhibitor component in the preservative solution can directly combine and precipitate with various inhibitors in feces, reducing the interference to nucleic acid detection.

This invention provides the use of compounds in the preparation of drugs for the prevention or treatment of RNA virus infections, wherein the compounds are any one of the following groups: (1) L-2-aminoadipic acid or a pharmaceutical salt thereof; (2) L-lysine or a pharmaceutical salt thereof. The compounds L-2-aminoadipic acid or L-lysine can significantly inhibit the production of infectious RNA virus particles and inhibit RNA virus replication within a non-toxic range. L-2-aminoadipic acid or L-lysine, as essential metabolites for the human body, have higher safety, and are widely available, inexpensive, and easily obtained.

The invention discloses a real-time fluorescent PCR (Polymerase Chain Reaction) detection method which comprises the following steps: (1) sample treatment: collecting a sample to be detected, and extracting pathogen nucleic acid by using a nucleic acid extraction kit; (2) reverse transcription: the pathogen is RNA virus, and cDNA is synthesized from the extracted RNA through reverse transcription reaction; (3) preparation of a PCR reaction system: preparing a reaction mixed solution containing the following components: a 2 * real-time fluorescence PCR premixed solution, a forward primer and a reverse primer aiming at pathogen specific genes, a fluorescence labeling probe and a cDNA template; (4) carrying out real-time fluorescent PCR amplification; and (5) analyzing a result. By adopting a low-adsorption reaction tube and a hot start enzyme technology, the limit of detection (LoD) is reduced to 10 copies / mL, which is about 5 times higher than that of the existing commercial kit. The specificity of the kit reaches 100%, no false positive exists, the kit is superior to a commercial kit (82%), the sensitivity (98%) of the kit is higher than that of the commercial kit (85%), and the detection rate of low-load samples (Ctgt, 30) is especially higher.

The invention discloses a nucleoside compound and application thereof, and mainly relates to a nucleoside compound as shown in a formula (I) or various prodrugs, stereoisomers, pharmaceutically acceptable salts and racemic compounds of the nucleoside compound, a pharmaceutical composition containing the formula (I) and application of the nucleoside compound or the prodrugs, the stereoisomers, the pharmaceutically acceptable salts and the racemic compounds in preparation of drugs for preventing and / or treating RNA virus infection. Furthermore, the compound disclosed by the invention has remarkable broad-spectrum anti-RNA virus activity, overcomes the instability of a raw medicine in water, has a good patent medicine prospect and good oral bioavailability, and can be used for preparing a medicine of a virus RNA dependent RNA polymerase inhibitor or a medicine composition containing the medicine and the like.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The invention discloses an injector-based nucleic acid purification device, an extraction method and a viral nucleic acid lysate. The purification device comprises an injector assembly and a filter membrane assembly, wherein the injector assembly comprises an injector tube barrel and a push rod matched with the injector tube barrel; the filter membrane assembly is connected to the outlet end of the injector tube barrel, and the filter membrane assembly is configured to be of a detachable structure. The nucleic acid purification device provided by the invention perfects the processes of nucleic acid release, nucleic acid washing and elution, can remove components which interfere with subsequent PCR (Polymerase Chain Reaction), fluorescent quantitative PCR and constant-temperature detection in the nucleic acid release process, and can improve the detection efficiency; the viral nucleic acid lysate is suitable for common clinical samples such as nasal swabs, anus swabs, serum and ascites, and is suitable for nucleic acid extraction and purification of DNA and RNA viruses by optimizing the proportion of guanidine isothiocyanate, polyvinylpyrrolidone (PVP-40) and lauryl sodium sulfate (SDS).

This invention belongs to the field of molecular biology detection technology, specifically relating to a Nipah virus (NiV) nucleic acid detection kit combining RT-LAMP and immunochromatography, and its application. This kit combines the high sensitivity and specificity of loop-mediated isothermal amplification (LAMP) technology with the rapid and visual interpretation advantages of immunochromatographic test strips, enabling on-site, rapid, and accurate detection of NiV. The core components of this invention include: a set of specific primers designed for conserved regions of the NiV gene, an optimized RT-LAMP reaction system, and specially treated immunochromatographic test strips for detecting LAMP amplification products. This kit eliminates the need for reverse transcription of RNA virus nucleic acids and expensive thermal cycling equipment. The entire detection process is completed within 20–30 minutes, with a sensitivity of up to 300 copies / μL. This solution combines the high efficiency of RT-LAMP technology with an intuitive, equipment-free detection method, achieving truly rapid and accurate on-site diagnosis of NiV.

The present invention relates to a modified CCA gene which encodes a CCA-adding enzyme, which modified CCA gene leads to resistance against a positive-strand RNA virus having a transfer RNA-like structure (TLS). The invention further relates to plants and seeds comprising the modified genes, methods for making and identifying such plants and use of the gene.

This invention discloses a traditional Chinese medicine composition for combating mandarin fish double RNA virus, comprising at least one of geniposide, baicalin, luteolin, magnolol, and mangiferin as active ingredients. The invention also discloses a method for preparing the traditional Chinese medicine composition and its applications. This invention can significantly inhibit the proliferation and replication of mandarin fish double RNA virus and significantly improve the survival rate of mandarin fish.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The present invention provides a combination comprising niclosamide and spironolactone for use in the treatment of diseases caused by RNA virus in a subject in need thereof. The present invention further provides a combination comprising niclosamide and spironolactone for simultaneous, separate, or sequential use.

The pharmaceutical use of the drug of the application is the pharmaceutical use of the broad-spectrum RNA virus drug of the application, i.e. the pharmaceutical use of the drug of the application in the treatment of the silkworm midgut type pyosis BmCPV. The drug of the application is dissolved in DMSO, and the concentration is 17.5 mg / mL. The drug of the application can inhibit the expression of the BmCPV S1 gene, and the treatment effect of the silkworm midgut type pyosis can be achieved. And the drug of the application can be continuously administered according to the dosage of the application, and the silkworm will not be negatively affected.